Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rock

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Journal of Human Genetics|March 8, 2019
Previously undescribed thyroid-specific miRNA sequences in papillary thyroid carcinomaMateus Camargo Barros-Filho, Michelle Pewarchuk, Brenda de Carvalho Minatel, et al.
Toxics|September 27, 2025
Toxicological, Chemical, Social, and Economic Challenges Associated with PFAS and Replacement Aqueous Film-Forming Foams (AFFF)William S Baldwin, Michael S Bloom, Katy W Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2021
Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapyAaron J Grossberg, Crosby D Rock, Jared Edwards, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 5, 2017
Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregionsAbdallah S R Mohamed, Carlos E Cardenas, Adam S Garden, et al.
Journal of Medicinal Chemistry|September 23, 2000
(S)-4-Methyl-2-(methylamino)pentanoic acid [4, 4-bis(4-fluorophenyl)butyl]amide hydrochloride, a novel calcium channel antagonist, is efficacious in several animal models of painY Song, S S Bowersox, D T Connor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 2022
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy VolunteersMark P Rubinstein, Cameron Williams, Caroline Mart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsKim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
JCI Insight|July 13, 2021
Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesionsJ Silvio Gutkind, Alfredo A Molinolo, Xingyu Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin LymphomaJennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
Oral Oncology|March 31, 2018
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancerMona Kamal, Sweet Ping Ng, Salman A Eraj, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Journal of Human Genetics|March 8, 2019
Previously undescribed thyroid-specific miRNA sequences in papillary thyroid carcinomaMateus Camargo Barros-Filho, Michelle Pewarchuk, Brenda de Carvalho Minatel, et al.
Toxics|September 27, 2025
Toxicological, Chemical, Social, and Economic Challenges Associated with PFAS and Replacement Aqueous Film-Forming Foams (AFFF)William S Baldwin, Michael S Bloom, Katy W Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2021
Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapyAaron J Grossberg, Crosby D Rock, Jared Edwards, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 5, 2017
Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregionsAbdallah S R Mohamed, Carlos E Cardenas, Adam S Garden, et al.
Journal of Medicinal Chemistry|September 23, 2000
(S)-4-Methyl-2-(methylamino)pentanoic acid [4, 4-bis(4-fluorophenyl)butyl]amide hydrochloride, a novel calcium channel antagonist, is efficacious in several animal models of painY Song, S S Bowersox, D T Connor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 2022
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy VolunteersMark P Rubinstein, Cameron Williams, Caroline Mart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsKim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
JCI Insight|July 13, 2021
Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesionsJ Silvio Gutkind, Alfredo A Molinolo, Xingyu Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin LymphomaJennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
Oral Oncology|March 31, 2018
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancerMona Kamal, Sweet Ping Ng, Salman A Eraj, et al.
Pageof 17